Chad Glasser is the Senior Director of Clinical Research at Tisento Therapeutics, a company focused entirely on developing treatments for mitochondrial disease. In this episode of Energy in Action, Chad speaks with host Marcy Young about the origins of Tisento, the science behind their lead compound Zagociguat, and why the company’s name—meaning “I hear you” in Italian—reflects their commitment to listening to patients.
They dive into the current PRIZM clinical trial for individuals with MELAS syndrome, including what makes this study unique: home visits, oral medication, and a crossover design that ensures all participants receive the active drug. Chad explains how the team shaped the trial based on patient interviews, and what’s next for the drug development process. For anyone living with mitochondrial disease—or considering participation in clinical research—this conversation offers clarity, hope, and a glimpse into the future of rare disease treatment.
Resources and Ways to Connect
Learn more about the PRIZM Trial:
Visit TisentoTX.com
Search for the PRIZM study on ClinicalTrials.gov
Stay Connected with MitoAction:
In this episode, Marcy welcomes returning guest Devin to unpack what happens after the diagnostic odyssey—whether you’ve received a genetic answer or are still...
PARENTS AS RARE - EPISODE 080 Jireh Somera - Fabry Fighter Jireh Somera is a husband, father and Fabry fighter. While our rare disease...
PARENTS AS RARE - EPISODE 036 Parenting with VCP Disease - Nathan Peck Nathan Peck is a husband, dad, VCP patient and the CEO...